Can thalidomide improve outcome in patients with multiple myeloma?

被引：0
|
作者：
Paul G Richardson
Constantine S Mitsiades
Nikhil C Munshi
Kenneth C Anderson
机构：
[1] the Clinical Director of the Jerome Lipper Multiple Myeloma Center (JLMMC) at the Dana-Farber Cancer Institute (DFCI),Instructor in Medicine at Harvard Medical School (HMS)
[2] the Department of Medical Oncology of DFCI and the Department of Medicine at Brigham and Women's Hospital,undefined
[3] the Associate Director of the JLMMC of DFCI,undefined
[4] Associate Professor of Medicine at HMS,undefined
[5] the Director of the JLMMC,undefined
[6] Chief of Division of Hematologic Neoplasia at DFCI and the Kraft Family Professor of Medicine at HMS,undefined
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：590 / 591
页数：1
相关论文
共 50 条
  • [41] Thalidomide in the treatment of multiple myeloma
    不详
    HAEMATOLOGICA, 2001, 86 (04) : 348 - 348
  • [42] Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
    Dhodapkar, Madhav V.
    Cooper, Dennis L.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 372 - 373
  • [43] Cyclophosphamide mobilization does not improve outcome in patients transplanted for multiple myeloma.
    Dingli, D
    Nowakowski, GS
    Dispenzieri, A
    Lacy, MQ
    Hayman, S
    Litzow, MR
    Gastineau, DA
    Gertz, MA
    BLOOD, 2005, 106 (11) : 340A - 340A
  • [44] Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
    Guglielmelli, T.
    Bringhen, S.
    Rrodhe, S.
    Gay, F.
    Cavallo, F.
    Berruti, A.
    Montefusco, V.
    Piro, E.
    Benevolo, G.
    Petrucci, M. T.
    Caravita, T.
    Offidani, M.
    Corradini, P.
    Boccadoro, M.
    Saglio, G.
    Palumbo, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (06) : 814 - 818
  • [45] Interferon-α-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM).
    Prince, HM
    Biagi, JJ
    Mitchell, P
    Mileshkin, L
    Seymour, JF
    Januszewicz, EH
    Wolf, MM
    Westerman, DA
    BLOOD, 2000, 96 (11) : 293B - 293B
  • [46] Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide.
    Badros, A
    Zangari, M
    Bodenner, D
    Siegel, E
    Spoon, D
    Toor, A
    Desikan, R
    Arnold, E
    Anaissie, E
    Zeldis, J
    Tricot, G
    Barlogie, B
    BLOOD, 2000, 96 (11) : 285B - 285B
  • [47] Thalidomide induced neuropathy in patients treated for multiple myeloma.
    Caravita, T
    Arciprete, F
    Siniscalchi, A
    Santinelli, S
    Iani, C
    Amadori, S
    BLOOD, 2002, 100 (11) : 385B - 385B
  • [48] Thalidomide maintenance therapy improves survival in patients with multiple myeloma
    Nature Clinical Practice Oncology, 2007, 4 (2): : 67 - 67
  • [49] Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
    Castro, T. B. M.
    Hallack Neto, A. E.
    Atalla, A.
    Ribeiro, L. C.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2016, 49 (06) : e5128
  • [50] The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma
    Grover, JK
    Uppal, G
    Raina, V
    ANNALS OF ONCOLOGY, 2002, 13 (10) : 1636 - 1640
12345